Theragenics Corporation (TGX) - 500 Beiträge pro Seite

[panik]

Profile:Theragenics Corporation operates as a medical device company serving the cancer treatment and surgical markets. The company operates through two segments, Brachytherapy Seed and Surgical Products. The Brachytherapy segment produces, markets, and sells TheraSeed, a cancer treatment device; I-Seed, an iodine-125 based prostate cancer treatment device; and related products and services. The Surgical Products segment offers wound closure and vascular access products, including sutures, needles, strips and tape, glues and other surgical sealants, and other surgical products for urology, veterinary, cardiology, orthopedics, plastic surgery, and dental applications. It also offers introducers and guide wires used in the interventional radiology and cardiology, and vascular surgery markets. The company sells its products through third-party distributors and directly to physicians, hospitals, and other healthcare providers in the United States, Canada, Puerto Rico, and internationally. Theragenics Corporation was founded in 1981 and is based in Buford, Georgia.


http://www.theragenics.com/

[amazing]

kgv von nur 18 für ein biotech wert

[cosine]

charttechnisch könnte der turnaround beginnen!

fundamental günstig!

[cosine]

charttechnisch könnte der turnaround beginnen!

fundamental günstig!

[panik]

Theragenics(R) Reports Revenue and Earnings for Second Quarter 2007
Thursday August 2, 7:02 am ET
Company Reports Record Quarterly and Six Month Revenue


BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE:TGX - News), a medical device company serving the prostate cancer treatment and surgical markets, today announced consolidated financial results for the second quarter and six months ended July 1, 2007. Consolidated revenue for the quarter was $15.6 million compared to $12.6 million in the second quarter of 2006, an increase of 24%. For the six-month period, consolidated revenue was $31.0 million, compared to $25.0 million in the 2006 period, also an increase of 24%. Net income for the quarter was $1.5 million, or $0.05 per share, compared to net income of $433,000, or $0.01 per share in the second quarter of 2006. For the six-month period, net income was $2.7 million, or $0.08 per share, compared to net income of $1.2 million, or $0.04 per share, in 2006.

Items affecting comparability between periods include an income tax benefit of $337,000 for the six-month period of 2006. This income tax benefit was from the release of a portion of the deferred tax valuation allowance, reducing the effective tax rate for that period. The 2007 periods included one-time interest income of $309,000 received in connection with a federal income tax refund. The 2006 periods included restructuring costs and gains on the sale of assets primarily related to the restructuring, resulting in $63,000 and $170,000 of net operating expenses for the second quarter and six-month period of 2006, respectively. Additionally, results for the 2006 periods did not include Galt Medical Corp., which was acquired on August 2, 2006.

"Our strategy to diversify is posting strong positive results," stated M. Christine Jacobs, Chairman, CEO & President. "This was our sixth consecutive quarter of record revenue and our best operating profit since the second quarter of 2002. Both business segments continued to deliver profitability, and cash flow was strong. We have transformed ourselves in less than two years and believe our future prospects have never been brighter."

Ms. Jacobs concluded, "We look forward to building upon the recent successes of strengthening our brachytherapy business and our diversification into surgical products. By maintaining our strength in brachytherapy and investing for growth in surgical products, we intend to sustain our positive momentum. We also intend to continue our growth and diversification via acquisition."

Tables I and II to this press release contain condensed consolidated statements of earnings and balance sheets. Revenue and operating income by segment is summarized in Table III, and Table IV includes a reconciliation of GAAP reported net earnings to earnings before interest, taxes, depreciation and amortization (EBITDA).

Theragenics will host a conference call today at 11:00 a.m. Eastern Time. To access the call, dial 800-538-9844 or 706-634-7274 and provide the conference ID code 10294096. This call is also being broadcast live over the Internet, and a recording will be available for one month on the Company's website. To access the webcast, log on to www.theragenics.com and select Investor Relations followed by selecting company presentations. You also can access a phone replay of the call until Midnight, August 9, 2007, by dialing 800-642-1687 or 706-645-9291 and providing the conference ID code: 10294096.

Theragenics Corporation (NYSE:TGX - News) operates two business segments: its brachytherapy seed business and its surgical products business. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. Its surgical products business manufactures and distributes wound closure and vascular access products. Wound closure products include sutures, needles and other surgical products with applications in, among other areas, urology, veterinary, cardiology, orthopedics, plastic surgery and dental. Vascular access includes introducers and guidewires used in the interventional radiology, interventional cardiology and vascular surgery markets. For additional information, call Theragenics' Investor Relations Department at [phone] or visit www.theragenics.com.

This press release contains non-GAAP financial measures used by Management in its analysis of the Company's operating performance. Management believes the presentation of financial measures excluding the impact of certain identified items provides supplemental information that is helpful to an understanding of the operating results of the Company's businesses and period-to-period comparisons of performance. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, the Company's reported GAAP results.

This release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future growth, opportunities and investments, and anticipated positive results in general. Actual results may differ materially due to a variety of factors, including, among other things, uncertainties related to the integration of acquired companies into the Theragenics organization, capitalization on opportunities for growth within the Surgical Products business, ability to recognize value from areas of shared expertise, risks and uncertainties related to competition within the medical device industry, development and growth of new applications within the markets for brachytherapy, wound closure, and vascular access and, more broadly, medical devices, competition from other companies within the brachytherapy, wound closure, vascular access and medical device markets, competition from other methods of treatment, new product development cycles, effectiveness and execution of marketing and sales programs, changes in product pricing, changes in costs of materials used in production processes, continued acceptance and demand of the Company's products by the markets in which it operates, introduction and/or availability of competitive products by others, potential changes in third-party (including CMS) reimbursement, physician training, third-party distribution agreements, ability to execute on acquisition opportunities on favorable terms and successfully integrate any acquisitions, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.

All forward looking statements and cautionary statements included in this document are made as of the date hereby based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward looking statement or cautionary statement.

TABLE I
Theragenics Corporation and Subsidiaries Condensed Consolidated
Statements of Earnings
(Unaudited)
(In thousands except per share data)

Three Months Ended Six months Ended
July 1, July 2, July 1, July 2,
2007 2006 2007 2006
------------------ ----------------
Product sales $15,364 $12,424 $30,591 $24,680
License fees 211 166 435 304
------------------ ----------------
Total revenue 15,575 12,590 31,026 24,984
Cost of sales 7,864 6,480 15,973 12,535
------------------ ----------------
Gross profit 7,711 6,110 15,053 12,449
Operating expenses:
Selling, general &
administrative 4,898 5,378 9,754 10,725
Amortization of
purchased intangibles 468 187 937 375
Research & development 379 179 670 418
Restructuring expenses - 63 - 369
Gain on sale of assets - - - (201)
------------------ ----------------
5,745 5,807 11,361 11,686
------------------ ----------------
Operating income 1,966 303 3,692 763
Non-operating items
Interest income 734 454 1,123 869
Interest expense (168) (65) (351) (134)
Other 1 1 2 (20)
------------------ ----------------
567 390 774 715
------------------ ----------------
Earnings before
income tax 2,533 693 4,466 1,478
Income tax expense 989 260 1,754 270
------------------ ----------------
Net earnings $ 1,544 $ 433 $ 2,712 $ 1,208
================== ================
Earnings per share:
Basic $ 0.05 $ 0.01 $ 0.08 $ 0.04
Diluted $ 0.05 $ 0.01 $ 0.08 $ 0.04
================== ================
Weighted average shares:
Basic 33,112 32,077 33,093 32,064
Diluted 33,264 32,120 33,236 32,114

TABLE II
Theragenics Corporation and Subsidiaries Condensed Consolidated
Balance Sheets
(Unaudited)
(In thousands)

Assets July 1, 2007 December 31, 2006
--------------------------------
Cash, short-term investments &
marketable securities $ 41,442 $ 32,980
Trade accounts receivable 7,998 7,556
Inventories 8,047 7,433
Deferred income tax asset 5,195 7,798
Assets held for sale 3,400 3,400
Prepaid expenses and other current
assets 1,204 3,478
--------------------------------
Total current assets 67,286 62,645
Property, plant & equipment, net 29,493 30,901
Goodwill 38,721 38,824
Other intangible assets 12,823 13,762
Other long-term assets 93 112
--------------------------------
Total assets $ 148,416 $ 146,244
================================

Liabilities & Shareholders' Equity
Current liabilities - accounts
payable & accrued expenses $ 4,399 $ 4,381
--------------------------------

Contract termination liability 1,501 1,513
Long-term debt 7,500 7,500
Deferred income tax liability,
long-term 4,963 6,148
Other long-term liabilities 663 561
--------------------------------
Total long-term liabilities 14,627 15,722

Shareholders' equity 129,390 126,141
--------------------------------
Total liabilities &
shareholders' equity $ 148,416 $ 146,244
================================

TABLE III
Theragenics Corporation and Subsidiaries
Segment Information
(Unaudited)
(In thousands)


Quarter Ended Six Months Ended
----------------- -----------------
July 1, July 2, July 1, July 2,
2007 2006 2007 2006
-------- -------- -------- --------
Revenue
Brachytherapy seed $ 8,551 $ 8,610 $17,200 $17,618
Surgical products 7,071 4,019 13,910 7,461
-------- -------- -------- --------
15,622 12,629 31,110 25,079
Intersegment eliminations
(47) (39) (84) (95)
-------- -------- -------- --------
Consolidated $15,575 $12,590 $31,026 $24,984
======== ======== ======== ========


Quarter Ended Six Months Ended
----------------- -----------------
July 1, July 2, July 1, July 2,
2007 2006 2007 2006
-------- -------- -------- --------
Operating income (loss)
Brachytherapy seed $ 940 $ (233) $ 2,090 $ (61)
Surgical products 1,029 528 1,607 837
-------- -------- -------- --------
1,969 295 3,697 776
Intersegment eliminations
(3) 8 (5) (13)
-------- -------- -------- --------
Consolidated $ 1,966 $ 303 $ 3,692 $ 763
======== ======== ======== ========

TABLE IV
Theragenics Corporation and Subsidiaries
Reconciliation of non-GAAP Financial Measures

Earnings Before Interest, Taxes, Depreciation and Amortization
(EBITDA), Excluding Special Items
(In thousands)

Quarter Ended Six Months Ended
------------------ ----------------
7/1/07 7/2/06 7/1/07 7/2/06
-------- --------- ------- --------
Net earnings, U.S. GAAP $ 1,544 $ 433 $2,712 $ 1,208
Income tax expense 989 260 1,754 270
Interest income (734) (454) (1,123) (869)
Interest expense 168 65 351 134
Other non-operating income/expense (1) (1) (2) 20
-------- --------- ------- --------
Operating income 1,966 303 3,692 763
Depreciation and amortization 1,572 1,236 3,139 2,432
Stock-based compensation
amortization 172 164 365 223
-------- --------- ------- --------
EBITDA 3,710 $ 1,703 7,196 $ 3,418
Restructuring related items,
net - 63 - 170
-------- --------- ------- --------
EBITDA excluding special items $ 3,710 $ 1,766 $7,196 $ 3,588
======== ========= ======= ========



Contact:
Theragenics Corporation
Frank Tarallo, 800-998-8479 or 770-271-0233
CFO & Treasurer
or
Lisa Rassel, 800-998-8479 or 770-271-0233
Manager of Investor Relations
www.theragenics.com

--------------------------------------------------------------------------------
Source: Theragenics Corporation

[50bager]

mittlerweile ein kgv von 17!!!!

[50bager]

nochmal nachgekauft